FDA to begin restructuring its inspection office in October

The FDA received an official go-ahead from HHS on Thursday, setting into motion its planned reorganization of its inspection operations around the globe, with an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Here’s what’s moving the needle in biotech stocks, in the final quarter of a dismal year

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good day.

October 2, 2023

Bedfont® Boosts Cancer Research Fundraising Efforts with £200 Donation

Local Med-tech company, Bedfont® Scientific Ltd., is proudly donating £200 to support the noble fundraising efforts of its employees, the Bedfont® Family, who ran the

July 18, 2023

Gilead aims to cash in on liver disease wave with $4.6bn CymaBay deal – Pharmaceutical Technology

Share this article Gilead Sciences announced a $4.6bn acquisition of CymaBay Therapeutics, expanding its liver disease portfolio. Credit: SOPA Images via Getty Images. Gilead Sciences

February 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.